<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01731457</url>
  </required_header>
  <id_info>
    <org_study_id>N N403 589338-WUM-PD-Poland</org_study_id>
    <nct_id>NCT01731457</nct_id>
  </id_info>
  <brief_title>Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function</brief_title>
  <official_title>Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are:&#xD;
&#xD;
        1. assessment of ischemia injury of kidney retrieved from standard and expanded criteria&#xD;
           deceased donor before transplantation&#xD;
&#xD;
        2. assessment of efficacy of kidney ischemia injury decreasing&#xD;
&#xD;
        3. assessment of influence of kidney ischemia injury decreasing on its function after&#xD;
           transplantation For the purpose of this research one hundred kidney will be retrieved&#xD;
           from deceased donors (standard and expanded criteria deceased donors) for&#xD;
           transplantation. All kidneys before transplantation will be stored in machine perfusion&#xD;
           in hypothermia with continuous flow - Organ Recovery Systems LifePort - each single&#xD;
           kidney in self-contained perfusion system.&#xD;
&#xD;
      For the kidney allograft assessment will be used measurements performed during machine&#xD;
      perfusion in hypothermia: renal flow, resistance, lactate dehydrogenase, lactates and&#xD;
      ischemia injury markers measured in the fourth hour of perfusion in perfusion fluid.&#xD;
&#xD;
      For kidney ischemia injury assessment such markers will be measured: tumour necrosis factor&#xD;
      (TNF alfa), interleukin 2 (IL-2), interleukin 6 (IL-6), high sensitivity C-reactive protein&#xD;
      (hsCRP), platelet-derived growth factor (PDGF), cystatin C, kidney Injury Molecule (KIM-1),&#xD;
      neutrophil Gelatinase-associated Lipocalin (NGAL), complement component C3, caspase 3.&#xD;
&#xD;
      Every time from pair of retrieved kidneys each kidney will be randomise for one of the group:&#xD;
&#xD;
        -  group 1) - 50 kidneys - examined group - &quot;cured&quot; with etanercept (ENBREL) in the first&#xD;
           hour of perfusion by adding drug to perfusion fluid,&#xD;
&#xD;
        -  group 2) - 50 kidneys - control group - without intervention. Ischemia injury markers&#xD;
           will be measured in perfusion fluid by kidney two times (in the first and fourth hour of&#xD;
           perfusion) for assessment of efficacy kidney ischemia injury decreasing.&#xD;
&#xD;
      Results of measurements of kidney ischemia injury before transplantation, parameters during&#xD;
      machine perfusion in hypothermia and donor parameters will be correlated with kidney&#xD;
      allograft function post transplantation.&#xD;
&#xD;
      Immediate, delayed and slow graft function, primary non-function, kidney function assessed by&#xD;
      creatinine concentration and creatinine clearance at one day, seven days, two weeks, 1, 6 and&#xD;
      12 months post transplantation and kidney graft survival 6 and 12 months post transplantation&#xD;
      will be analysed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>delayed graft function</measure>
    <time_frame>one week</time_frame>
    <description>a need at least one dialysis during first week after transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12 months graft survival</measure>
    <time_frame>12 months</time_frame>
    <description>survival of kidney grafts 12 months after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute rejection</measure>
    <time_frame>12 months</time_frame>
    <description>biopsy proven acute rejection episodes during the first year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney ischemia injury assessment</measure>
    <time_frame>4 hours</time_frame>
    <description>ischemia injury markers measured two times (in the first and fourth hour of perfusion) in perfusion fluid: tumour necrosis factor (TNF alfa), interleukin 2 (IL-2), interleukin 6 (IL-6), high sensitivity C-reactive protein (hsCRP), platelet-derived growth factor (PDGF), cystatin C, kidney Injury Molecule (KIM-1), neutrophil Gelatinase-associated Lipocalin (NGAL), complement component C3, caspase 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Transplanted Kidney Ischemia Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>adding appropriate dose of etanercept to the perfusion fluid</description>
    <arm_group_label>Etanercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        DONOR STAGE&#xD;
&#xD;
          -  donor after brain death&#xD;
&#xD;
          -  seronegative HCV (hepatitis C virus)&#xD;
&#xD;
          -  procurement of two kidneys from the same donor&#xD;
&#xD;
          -  donor center distance up to 220 kilometres from Warsaw&#xD;
&#xD;
          -  availability of fluid KPS-1 and cartridge of Organ Recovery System&#xD;
&#xD;
        RECIPIENT STAGE&#xD;
&#xD;
          -  recipient of kidneys from deceased donor&#xD;
&#xD;
          -  at least eighteen recipient&#xD;
&#xD;
          -  expression of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        DONOR STAGE&#xD;
&#xD;
          -  live kidney donor&#xD;
&#xD;
          -  seropositive HCV (hepatitis C virus)&#xD;
&#xD;
          -  get only one from the kidneys&#xD;
&#xD;
          -  &quot;doubtful&quot; donor - e.g. need for biopsy because of proteinuria or due to histological&#xD;
             lesions (e.g. tumor)&#xD;
&#xD;
          -  donor center distance above 220 kilometres from Warsaw&#xD;
&#xD;
          -  lack of fluid KPS-1 and cartridge of Organ Recovery System&#xD;
&#xD;
        RECIPIENT STAGE&#xD;
&#xD;
          -  recipient of kidney form living donor&#xD;
&#xD;
          -  minor recipient&#xD;
&#xD;
          -  no expression of informed consent&#xD;
&#xD;
          -  multiple organ recipient&#xD;
&#xD;
          -  recipient &quot;EN BLOC&quot; kidneys or two kidneys&#xD;
&#xD;
          -  recipient of kidney from donor under 14 years old&#xD;
&#xD;
          -  a need of atypical urinary diversion in kidney recipient&#xD;
&#xD;
          -  participation in another study at least in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Domagala, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of General Surgery and Transplantation</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>02-006</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>November 15, 2012</study_first_submitted>
  <study_first_submitted_qc>November 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2012</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Piotr Domaga≈Ça</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ischemia, reperfusion, kidney, transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

